NASDAQ:KLRS Kalaris Therapeutics Q3 2025 Earnings Report $2.94 +0.02 (+0.68%) As of 02:01 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Kalaris Therapeutics EPS ResultsActual EPS-$0.64Consensus EPS -$0.66Beat/MissBeat by +$0.02One Year Ago EPSN/AKalaris Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AKalaris Therapeutics Announcement DetailsQuarterQ3 2025Date11/12/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Kalaris Therapeutics Earnings HeadlinesKalaris to Present at Morgan Stanley 24th Annual Global Healthcare ConferenceAugust 31, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Airsculpt Technologies (AIRS), Biohaven Ltd. (BHVN) and Kalaris Therapeutics (KLRS)August 15, 2026 | theglobeandmail.comManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 in one quarter. Institutions own about 83% of shares, including BlackRock's 32 million shares worth $716 million and Vanguard's 48 million shares worth nearly $1.1 billion. A new multi-year deal with Palantir adds an AI-driven edge to this energy producer's operations.September 28 at 1:00 AM | Monument Traders Alliance (Ad)Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO) and Kalaris Therapeutics (KLRS)August 13, 2026 | theglobeandmail.comKalaris Therapeutics, Inc.: Kalaris Reports Second Quarter 2026 Financial Results and Provides Business UpdatesAugust 11, 2026 | finanznachrichten.deKalaris Reports Second Quarter 2026 Financial Results and Provides Business UpdatesAugust 11, 2026 | finance.yahoo.comSee More Kalaris Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Kalaris Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kalaris Therapeutics and other key companies, straight to your email. Email Address About Kalaris TherapeuticsKalaris Therapeutics (NASDAQ:KLRS), Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for retinal vascular diseases and other serious eye disorders. Its research programs are aimed at addressing diseases in which abnormal blood-vessel growth or leakage can impair vision. The company’s activities include the discovery and clinical development of investigational ophthalmic medicines intended to improve outcomes for patients with retinal conditions. Kalaris Therapeutics has not yet established a broad portfolio of marketed products, and its principal programs remain in development. Publicly available information about the company’s broader operating history, geographic reach and leadership is limited. Kalaris Therapeutics is based in the United States and serves the global biopharmaceutical market through its research and clinical-development activities.View Kalaris Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Brewing Trouble? Starbucks Spills the Beans on 250 Store ClosuresMarketBeat Week in Review – 09/21 - 09/25Analyst Rating Boosts May Signal More Upside for These 3 Stocks3 Stocks Under the Microscope After Large Insider Sales3 Healthcare Stocks Showing Why the Sector Still Has Momentum2 Cybersecurity Stocks Breaking Out as AI Continues to Be a TailwindFertilizer Prices Keep Climbing: 3 Stocks Still Trading at a Discount Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
